华润医药(03320.HK) 宣布,集团旗下华润昂德生物药业有限公司递交的注射用重组人组织型纤溶酶原激酶衍生物(瑞通立)的新适应症上市申请已获批,用于急性缺血性卒中(AIS)患者的溶栓治疗。
瑞通立作为第三代静脉溶栓药物,仅包含天然组织型纤溶酶原激活剂对纤维蛋白的高度特异性和酶活性区域,具有更长的半衰期,更强的溶栓效果。而卒中是中国乃至全球的主要死亡原因之一,具有高死亡率和高致残率的特点。中国每年约有200万卒中新发病例,其中缺血性卒中约占80%,而静脉溶栓是目前缺血性卒中的主要治疗方式。(ad/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-24 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.